Objective: To measure effects of low osmolar non ionic contrast media on cystatin–C serum levels on different days after administration. Material and Method: Twenty-two oryctalagus cuniculus were divided into two groups of 11 subjects, each subject receiving intravenous injection of low osmolar non ionic contrast or a placebo solution (NaCl 0,9%). Cystatin-C serum levels of each subject were measured before injection, on days 1, 3, 7, and 10. Cystatin–C serum levels were determined with a sandwich ELISA method. Statistical analysis was performed with t–test. Results: Mean cystatin–C serum levels before injection was 0,00337 ± 0,00101 mg/L. Means from days 1, 3, 7, and 10 after injections were 0,00498 ± 0,00153 mg/L; 0,00565 ± 0,00247 mg/L; 0,00468 ± 0,00157, and 0,00339 ± 0,00188 mg/L respectively. Conclusion: Increase in serum cystatin–C levels on days 1, 3, and 7 was significant. On the 10th day no significant escalation was observed. Compared to the control group, there were significant differences in serum cystatin–C increase on days 1 and 3 in the intervention group, but no significant differences 7 and 10 days after injection.
Cystatin–C serum, low osmolar non ionic contrast media, oryctalagus cuniculus
Waybill MM, Waybill PN. Contrast media – induced nephrotoxicity: Identification of patients at risk and algorithms for prevention. 2001; 12: 3 – 9. <http://www.jvir.org/cgi/reprint/12/1/3> [diakses 28 September 2006].
Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast - induced nephropathy: State of the art. 2005. p. 1542 – 50. <http://ndt.oxfordjournals.org/cgi/reprint/20/8/1542> [diakses 28 September 2006].
Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors, and preventive strategies. May 2005: 172 (11)
<http://www.cmaj.ca/cgi/reprint/172/11/1461> [diakses 28 September 2006].
Tepel M, Aspelin P, Lameire N. Contrast – induced nephropathy: A clinical and evidence – based approach. 2006; 113: 1799 – 806. <http://circ.ahajournals.org/cgi/reprint/113/14/1799> [diakses 28 September 2006]
Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. 2003; 76: 513 – 8. <http://bjr.birjournals.org/cgi/reprint/76/908/513>[diakses 28 September 2006].
Lameire NH. Contras – induced nephropathy – prevention and risk reduction. Oxford University Press. Nephrol Dial Transplant 2006; 21 [Suppl 1]: i11 – i23.
Orlando R, Mussap M, Plebani M, Piccoli P, Martin SD, Floreani M, et al. Diagnostic value of plasma cystatin-C as a glomerular filtration marker in decompenseted liver cirrhosis. Clinical Chemistry 2002; 48: 850 – 8.
Reed CH. Diagnostic application of cystatin-C. British Journal of Biomedical Science 2000; 57: 323 – 9.
Herget-Rosenthal S, Trabold S, Pietruck F, Heemann U, Philipp T, Kribben A. Cystatin-C: Efficacy as screening test for reduced glomerular filtration rate. American Journal of Nephrology 2000; 20: 97 – 102.
Katzberg RW. Urography into the 21st century: New contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997; 204: 297 – 312.
Halilintar I. Perbandingan antara cystatin-C serum dengan klirens kreatinin sebagai marker endogen untuk mengukur fungsi ginjal pada pasien batu saluran kemih obstruktif. Jurnal Urologi Indonesia 2006; 13 (2): 39 – 43.
Hariyono. Pengaruh obstruksi ureter total unilateral buatan terhadap kadar cystatin-C serum oryctalagus cuniculus. Jurnal Urologi Indonesia; 2007: 14 (2).
Dharnidharka VR. Serum cystatin-C is superior to serum creatinin as a marker of kidney function: A meta-analysis. American Journal of Kidney Diseases; August 2002: 40 (2).
Coll E, Botey A, Alvares L, Poch E, Quinto L, Saurina A. Serum cystatin-C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. American Journal of Kidney Diseases; Juli 2000: 36 (1).